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Abstract Mitochondrial Superoxide dismutase (MnSOD) is 
usually diminished in cancer cells. We observed that in vivo 
treatment with LPS produces a strong increase of MnSOD 
mRNA levels and a weak induction of an inactive protein in rat 
hepatocarcinomas. In normal liver iron deficiency, obtained with 
desferrioxamine administration, produces a decrease in the 
MnSOD induction by LPS, indicating that such induction could 
depend on tissue iron content. However, no change in MnSOD 
mRNA has been observed in iron-overloaded tumor tissue. Thus, 
iron is possibly involved in the transcriptional regulation of the 
protein, in combination with some other unknown factor that 
appears to be deficient in tumor cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Reactive oxygen species (ROS) such as H2O2 and 0'2 are 
recognized to be involved in both the initiation and promo-
tion phases of carcinogenesis [1]. 
The Superoxide dismutases (SODs) are metalloproteins 
found both in prokaryotic and eukaryotic cells and their func-
tion is to scavenge 0"2 radicals. In mammalian tissues three 
major types of SOD exist: the copper-zinc containing SOD 
(CuZnSOD) localized in the cytosol, the extracellular SOD 
(EC-SOD) localized in extracellular fluids and the manganese 
containing SOD (MnSOD) found in the mitochondrial matrix 
[2-4]. It has been reported that MnSOD activity is decreased 
in transplantable tumors in vivo and tumor cell lines in vitro 
[5,6] but it is still uncertain whether the decrease of MnSOD 
in tumor tissues is related to a change in the dosage of 
MnSOD gene. 
Previous works reported that the deficiency of this metal-
loenzyme would depend on the decrease of gene dosage. In-
deed, a close association between the diminution of MnSOD 
activity, immunoreactive protein, mRNA and deletion of 
chromosome segment 6q21, where the gene is mapped, has 
been observed in several tumor cell lines [7]. Moreover, since 
the introduction of human chromosome 6 in human melano-
ma cells can suppress the malignant phenotype [8] and in 
human breast cells the overexpression of MnSOD has been 
reported to revert the malignant phenotype [9], MnSOD gene 
has been proposed to act as a tumor-suppressor gene [10]. 
On the other hand, in contrast to these observations, it was 
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found that in transformed human lung fibroblasts (SV-40/WI-
38), which are characterized by a significant degree of deletion 
of segment 6q21, there is no change in the dosage of the 
MnSOD gene or defect in the primary structure of the pro-
tein, although reduced levels of MnSOD activity, immuno-
reactive protein and mRNA are present [11]. 
Changes in MnSOD expression have been observed both in 
vitro and in vivo in normal eukaryotic cells and in tumor 
tissues, in response to a variety of physical or chemical agents 
[12-15]. 
Previously, in our laboratory, we obtained evidence in favor 
of a down-regulation of MnSOD at the (pre-)transcriptional 
level in poorly differentiated rat hepatocarcinomas where iron 
and manganese ions have been found to be markedly reduced 
[16,17]. 
In this study we examined the effects of the bacterial endo-
toxin lipopolysaccharide in tumor tissues in vivo. We used as 
experimental models the highly malignant rat hepatocarcino-
ma Morris 3924A (HCC) and liver from healthy rats. Treat-
ment consisted of administration of LPS, a recognized medi-
ator of the inflammatory response, able to stimulate TNF-a 
production in vivo. 
Since we proposed that iron deficiency could be a factor 
responsible for the down-regulation of MnSOD in cancer cells 
[17], we thought to produce iron depletion in rat liver and iron 
overload in HCC tissue, in order to study the regulation of 
MnSOD after LPS induction and its relationship with the iron 
tissue content. 
2. Materials and methods 
2.1. Animals, tumors and treatments 
Morris 3924A hepatomas (poorly differentiated and fast-growing) 
were propagated by subcutaneous transplantation in ACI/T inbred 
rats [6]. The tumors were utilized after 3^1 weeks of growth. Livers 
from normal inbred ACI/T were used as control. 
Rats were treated intraperitoneally with 5, 10, 20, or 22.5 mg LPS/ 
kg b.w. and killed after 18 h (LPS from Escherìchia coli 0111:B4, 
Sigma). Desferrioxamine (Desferal, from Ciba-Geigy S.A.) was ad-
ministered intramuscularly at a dose of 200 mg/kg b.w./day for 
3 days before LPS treatment. Iron (Ferlixit from Rhone-Poulenc 
Rorer) was administered intravenously at a dose of 20 mg/kg b.w./ 
day for 3 days before LPS treatment. 
2.2. mRNA isolation and Northern Mot analysis 
Total RNA was isolated according to the method of Chirgwin et al. 
[18]. RNA concentrations were determined spectrophotometrically by 
absorbance at 260 nm. Samples of denatured RNA were size-fractio-
nated by formaldehyde-agarose (1.5%) gel electrophoresis and capil-
lary transferred to nylon membranes. Blots were prehybridized for 5 h 
at 42°C and hybridized to CuZnSOD and MnSOD cDNA probe 
overnight at the same temperature. The cDNA probe was radiola-
belled with [a-32P]dCTP using a Multiprime DNA labelling system 
(Amersham). Autoradiograms were obtained at 70°C using Kodak 
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Fig. 1. Levels of CuZnSOD and MnSOD mRNA in liver and hepatocarcinoma (HCC) treated with 10 mg/kg b.w. LPS. Values are means 
±S.E. from ?>-A experiments. MnSOD mRNA levels correspond to the sum of the intensities of the two major hybridizing bands (1080 and 
850 nt) normalized to 100% for control liver. 
XAR film. The intensity of autoradiograms was scanned with a trans-
mission densitometer. 
2.3. Superoxide dismutase activities 
The tissues were excised and rinsed in saline to remove contaminat-
ing blood and then homogenized on ice in 0.05 M potassium phos-
phate, 0.1 mM EDTA, pH 7.4 for 2 min at full speed with a Polytron 
homogenizer. Proteins were estimated with the biuret method. 
MnSOD activity was assayed on 48 h-dialyzed homogenate of tumor 
and normal tissue specimens by the method of inhibition of hematox-
ylin autoxidation to hematein [19], monitored at 560 nm, at pH 7.5 
and 25°C, using a standard curve obtained with purified bovine blood 
enzyme. MnSOD was measured in the presence of 1.5 mM Na cya-
nide. 
2.4. Western blot analysis 
SDS-polyacrylamide gel electrophoresis was performed on a 12.5% 
gel, with a 3% stacking gel. Gels were each 2 mm thick. 30 ug of total 
protein/well was loaded for the detection of MnSOD. After SDS-
PAGE, proteins were horizontally electroluted into nitrocellulose pa-
per with a transfer time of 1 h and a voltage of 100 mV. Immunoblot 
detection of the enzyme was performed with the monoclonal antibody 
directed against the rat MnSOD protein [20]. 
2.5. Ion content measurements 
Metal concentrations were determined by atomic absorption using a 
Perkin-Elmer 272 spectrophotometer utilizing thin slices of fresh tis-
sues dried overnight at 100°C and digested with 1 N nitric acid. 
3. Results 
3.1. Effects of LPS treatment on MnSOD in rat 
hepatocarcinomas and livers 
In order to elucidate the molecular mechanisms responsible 
for the M n S O D alteration in cancer tissues we investigated in 
H C C and in rat hepatocytes the in vivo effects of LPS on 
M n S O D expression. In this experimental model we evaluated 
the activity, the immunoreactive protein and the m R N A of 
M n S O D . 
A significant increase (about 15 times compared to the un-
treated tissue) in m R N A levels for M n S O D was observed in 
the liver of rats treated with LPS (10 mg/kg b.w. 18 h after 
treatment). In the tumor the M n S O D m R N A was also in-
creased by LPS treatment, but it was only 7 times higher 
Fig. 2. Western blot of MnSOD in liver and HCC of rats treated with different doses of LPS: HCC of rats treated with 2.5, 5, 10 or 22 mg/kg 
b.w. LPS (lanes 1-5 respectively); HCC of control rat (lane 6); liver of rats treated with 2.5, 5 or 20 mg/kg b.w. LPS (lanes 7-9 respectively); 
liver of control rats (lane 10). The major MnSOD band represents a 24 kDa protein. 
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Table l 
Superoxide dismutase activities in hepatocarcinoma (HCC) and liver of control and treated rats 
Treatment MnSOD (|ig/g wet weight) CuZnSOD (jig/g wet weight) 
Control liver 206.0±31.7 (7) 355.5±23.2 (7) 
Liver+LPS 246.0 ±24.6 (5) 354.1 ± 19.3 (5) 
Liver+desferrioxamine 173.3 ±21.3 (5) 354.6 ±32.6 (5) 
Liver+desferrioxamine+LPS 215.6±35.0 (5) 330.1 ±61.6 (5) 
Control HCC 22.7 ±4.2 (5) 23.0 ±1.2 (5) 
HCC+LPS 21.0±3.3 (5) 25.4±0.05 (5) 
HCC+iron+LPS 19.3 ±2.5 (5) 22.9 ±3.9 (5) 
Values are means ± S.E. Numbers in parentheses indicate the number of livers or hepatocarcmomas. 
than that observed in control HCC. The stimulation with LPS 
did not affect the level of CuZnSOD mRNA, demonstrating a 
selective induction for the mitochondrial enzyme (Fig. 1). 
The MnSOD protein contents of livers and tumors of rats 
treated with different doses of LPS were estimated by immu-
nological staining in Western blots. Fig. 2 shows that in hep-
atocarcmomas from treated rats different doses of endotoxin 
(lanes 1-5) induced the 24 kDa band of MnSOD, which is 
nearly absent in the control HCC (lane 6), and a 25 kDa 
band, presumably corresponding to the cytosolic precursor 
of the protein [24]. The enzymatic activity, on the contrary, 
was not increased (Table 1). In rat HCC LPS also produced 
an increase of peptides of lower molecular weight (22 kDa 
band, recognized by the monoclonal antibody against rat 
MnSOD), which could likely be degradation products of 
MnSOD protein. 
In treated rat livers (Fig. 2), only the 22 kDa band (lane 9) 
was induced by LPS compared to the control (lane 10) and 
only by a high dose of LPS (20 mg/kg b.w.). Lower doses of 
LPS (2.5 and 5 mg/kg b.w.) did not affect MnSOD content 
(lane 7, 8). In rat liver, LPS did not produce any increase of 
the 24 kDa band (Fig. 2). 
The activity of the mitochondrial enzyme was slightly in-
creased by LPS (10 mg/kg b.w.) in rat liver and unchanged in 
tumor tissues (Table 1). 
3.2. Effect of iron and desferrioxamine treatments on MnSOD 
in rat hepatocarcmomas and in rat liver 
In order to determine if iron plays a role in the regulation 
of gene expression of MnSOD in normal and tumor cells, we 
modulated iron content in rat liver and HCC. We treated 
healthy ACI/T rats with the iron chelator desferrioxamine 
(DESF) in order to decrease the iron tissue content and sup-
plemented tumor-bearing rats with iron to increase the metal 
content. 
The amount of iron in hepatocarcinoma cells is about 40% 
of that in normal hepatocytes (Fig. 3). A 3 day administration 
of the iron chelator DESF caused a 20% reduction of iron 
content in rat liver (Fig. 3) and this condition strongly re-
duced the induction of MnSOD mRNA obtained in response 
to LPS (Fig. 4). This finding suggests that iron can be in-
volved in MnSOD regulation. On the other hand, the hepatic 
levels of MnSOD mRNA were almost unchanged after DESF 
administration without LPS stimulation (Fig. 4). Table 1 
shows that MnSOD activity was almost the same in the livers 
of animals treated with DESF or with DESF plus LPS ; more-
Fig. 3. Iron and manganese content in control liver and liver from rats treated with desferrioxamine (DESF), and DESF+LPS, in control 
HCC, HCC after iron overloading (HCC+Fe) and HCC with iron overloading plus LPS (HCC+Fe+LPS). Results are expressed as % of con-
trol liver (7 ug Mn and 350 ug Fe/g dry weight). Values are means ± S.E. from 6-7 rats. 
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Fig. 4. Northern blot hybridization of MnSOD cDNA probe with 
total RNA isolated from rat liver treated with 10 mg/kg b.w. LPS, 
with the iron chelator DESF, control liver and liver pretreated with 
DESF plus LPS (lanes \-4 respectively). The three minor bands 
were estimated to be about 4100, 3000 and 2100 nt and the two ma-
jor band 1080 and 850 nt. 
over, the immunoreactive protein was unchanged (data not 
shown). 
Iron supplementation in rats bearing HCC produced a 50% 
increase of this metal in tumor tissue. The metal content ob-
tained by iron overloading in tumor cells is still lower than in 
normal hepatocytes and it was not affected by LPS adminis-
tration (Fig. 3). In the above experiments a modest increase of 
manganese content was also observed. This can be presum-
ably attributed to the increase of saturation by Fe loading of 
plasma transferrin, a common carrier of the two ions [21,22]. 
The effect of LPS treatment on MnSOD mRNA was the 
same in the iron supplemented and the non-supplemented 
tumor tissues (Fig. 5). Moreover, in rat HCC we observed a 
decrease of the immunoreactive protein after iron treatment 
(Fig. 6). 
4. Discussion 
Tumor cells are known to differ biochemically in many 
ways from normal cells. Among the differences, a lack of 
Fig. 5. Northern blot hybridization of MnSOD cDNA probe with 
11 ug of total RNA isolated from HCC with iron overload, control 
HCC, HCC treated with LPS and HCC with iron plus LPS (lanes 
1-4 respectively). 
MnSOD activity in vivo and in vitro has been reported (see 
[23] for review). The Mn-containing SOD is an inducible en-
zyme [2] and ROS are one of the major factors that regulate 
MnSOD gene expression [24]. We have used a rat hepatocar-
cinoma with a low degree of differentiation and control nor-
mal liver as models to study the mechanisms involved in the 
control of MnSOD gene expression in tumor cells in vivo. 
In this study, we demonstrated that it is possible to induce 
the expression of MnSOD in vivo in the tumor using LPS. 
This bacterial endotoxin can increase mitochondrial Superox-
ide dismutase expression in cell lines and in normal cells in 
vitro [13] and in stomach of rat in vivo [14] with a mechanism 
that is thought to stem from a response to the intracellular 
generation of cytokines, such as TNFoc, and oxidants. The 
MnSOD induction by LPS may derive from cytokine involve-
ment or from direct activation of the enzyme as part of the 
initial phase of the acute inflammatory response [25]. More-
over, LPS treatment appears to up-regulate the transcription 
factor AP-1 [26], one of the possible candidates involved in 
MnSOD gene expression. 
In this work we obtained a strong MnSOD mRNA increase 
in both normal and tumor liver tissue following LPS treat-
ment. In addition, we observed that the extent of the induc-
tion is less pronounced in tumor tissue than in normal tissue. 
MnSOD activity was also increased, albeit at a low level, in 
Fig. 6. Western blot analysis of HCC (lane 6) and liver (lane 3) of control rats, iron treated rat liver (lane 2), iron+LPS treated rat liver (lane 
1) and HCC of iron treated rat (lane 5). Lane 4, molecular weight standard. The major MnSOD band represents a 24 kDa protein. 
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normal liver. In contrast, no significant increase of enzymatic 
activity was observed in the tumor, in spite of M n S O D 
m R N A and immunoprotein up-regulation. 
In accordance with the observed increase of degradation 
products in LPS treated tumor tissue, previous investigations 
reported that LPS induces oxidative damage mediated by in-
creased production of R O S and N O ' [27,28], with an increase 
in lipid peroxidation and an alteration of the C a 2 + permeabil-
ity of hepatocyte plasma membranes [29]. ROS are thought 
also to induce the transcription of early genes such as c-fos, c-
jun, c-myc [30] or to activate directly DNA-binding proteins 
and transcription factors such as NF-kB and AP-1 [31]. 
In order to establish whether iron is involved in the regu-
lation of M n S O D , we tried to mimic in rat liver by desferriox-
amine treatment a condition of iron deficiency similar to that 
found in rat H C C [17]. In such experiments we observed a 
strong diminution of inducibility of the enzyme by LPS, sup-
porting the above mentioned hypothesis. Nevertheless, the 
lack of induction of M n S O D m R N A in the iron overloading 
condition demonstrates that the metal alone is unable to up-
regulate the enzyme. Altogether, the data reported suggest 
that induction of M n S O D by LPS depends partially on the 
iron tissue content and on factor(s) which are supposed to be 
lacking in highly malignant tumor cells. 
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